STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

ABUS ARBUTUS BIOPHARMA CORPORATION StockScouter® Report

4

StockScouter® Score

ARBUTUS BIOPHARMA CORPORATION, a small cap growth company in the healthcare sector, is expected to perform in line with the market over the next six months with higher than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The most recent quarterly earnings report higher than analysts’ consensus forecast. Positive
  • The multi-period measure of relative price change and consistency is above average. Positive/Neutral

 

Concerns

  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
  • Earnings growth in the past year has decelerated rapidly compared to earnings growth in the past three years. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that small cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 100% done.
Progress: 60% done.
Low
High

Core Model Grades

B
N/A
D
B

Previous Ratings

4
2
1